Home > Annual Financials > SUVEN LIFE SCIENCES

SUVEN LIFE SCIENCES Financial Statement Analysis
[BOM: 530239|NSE : SUVEN]

The Revenues of SUVEN LIFE SCIENCES have increased by 6.90% YoY .
The Earnings Per Share (EPS) of SUVEN LIFE SCIENCES has decreased by Negative YoY.
COMMUNITY POLL
for SUVEN LIFE SCIENCES
Please provide your vote to see the results

SUVEN LIFE SCIENCES Last 5 Annual Financial Results
[BOM: 530239|NSE : SUVEN]

ConsolidatedMar2026
Mar2025
Mar2024
Mar2023
Mar2022
Revenues ₹7.12 Cr₹6.66 Cr₹12 Cr₹14 Cr₹12 Cr
Expenses ₹291 Cr₹172 Cr₹140 Cr₹139 Cr₹134 Cr
Operating Profit (Excl OI) ₹-284 Cr₹-166 Cr₹-128 Cr₹-126 Cr₹-122 Cr
Other Income ₹14 Cr₹11 Cr₹21 Cr₹8.45 Cr₹1.60 Cr
Interest ₹0.31 Cr₹0.17 Cr₹0.30 Cr₹0.41 Cr₹0.67 Cr
Depreciation ₹5.61 Cr₹5.82 Cr₹6.50 Cr₹6.54 Cr₹4.39 Cr
Profit Before Tax ₹-276 Cr₹-161 Cr₹-106 Cr₹-118 Cr₹-122 Cr
Profit After Tax ₹-276 Cr₹-161 Cr₹-105 Cr₹-118 Cr₹-122 Cr
Consolidated Net Profit ₹-276 Cr₹-161 Cr₹-105 Cr₹-118 Cr₹-122 Cr
Earnings Per Share (Rs)₹-10.48₹-7.37₹-4.82₹-5.42₹-8.39
PAT Margin (%)-3,884.13-2,415.11-898.63-873.52-1,029.99
ROE(%)-101.80-84.88-32.56-50.17-145.90
ROCE(%)-78.71-84.51-32.78-49.94-117.81
Total Debt/Equity(x)0.000.000.000.000.01

Key Financials

Market Cap : ₹ 8,678.6 Cr
Revenue (TTM) : ₹ 7.1 Cr
Net Profit(TTM) : ₹ -276.3 Cr
EPS (TTM) : ₹ -9.8
P/E (TTM) : -

Industry Peers & Returns1W1M1Y
SUVEN LIFE SCIENCES -1.5% 2.8% 5.1%
SUN PHARMACEUTICAL INDUSTRIES 0.8% 6.3% 18.2%
DIVIS LABORATORIES 8.6% 20.7% 18.5%
TORRENT PHARMACEUTICALS 1.7% 9.4% 38.5%
CIPLA 4.5% 1.2% -1.4%
DR REDDYS LABORATORIES -0.3% -14.8% -9.5%
MANKIND PHARMA -3.2% -0.7% -0.4%
LUPIN 0.2% 0.6% 24.5%
ZYDUS LIFESCIENCES 1.7% 2.4% 14.9%


SUVEN LIFE SCIENCES Revenues
[BOM: 530239|NSE : SUVEN]

Y-o-Y

6.90 %

5 Yr CAGR

-11.96 %

Years Revenues % Change
Mar2026 ₹7.12 Cr
6.90
Mar2025 ₹6.66 Cr
-43.08
Mar2024 ₹12 Cr
-13.63
Mar2023 ₹14 Cr
14.31
Mar2022 ₹12 Cr -


SUVEN LIFE SCIENCES Operating Profit
[BOM: 530239|NSE : SUVEN]

Y-o-Y

Negative

5 Yr CAGR

Negative

Years Operating Profit % Change
Mar2026 ₹-284 Cr
Negative
Mar2025 ₹-166 Cr
Negative
Mar2024 ₹-128 Cr
Negative
Mar2023 ₹-126 Cr
Negative
Mar2022 ₹-122 Cr -

Operating Margins
Y-o-Y

Negative

5 Yr CAGR

Negative

Years Operating Margin% % Change
Mar2026 -3996.56%
Negative
Mar2025 -2488.79%
Negative
Mar2024 -1093.52%
Negative
Mar2023 -928.89%
Negative
Mar2022 -1032.16% -

SUVEN LIFE SCIENCES Profit After Tax
[BOM: 530239|NSE : SUVEN]

Y-o-Y

Negative

5 Yr CAGR

Negative

Years Profit After Tax % Change
Mar2026 ₹-276 Cr
Negative
Mar2025 ₹-161 Cr
Negative
Mar2024 ₹-105 Cr
Negative
Mar2023 ₹-118 Cr
Negative
Mar2022 ₹-122 Cr -

PAT Margins
Y-o-Y

Negative

5 Yr CAGR

Negative

Years PAT Margin(%) % Change
Mar2026 -3884.13 %
Negative
Mar2025 -2415.11 %
Negative
Mar2024 -898.63 %
Negative
Mar2023 -873.52 %
Negative
Mar2022 -1029.99 % -

SUVEN LIFE SCIENCES Earnings Per Share (EPS)
[BOM: 530239|NSE : SUVEN]

Y-o-Y

Negative

5 Yr CAGR

Negative

Years EPS % Change
Mar2026 ₹-10
Negative
Mar2025 ₹-7.37
Negative
Mar2024 ₹-4.82
Negative
Mar2023 ₹-5.42
Negative
Mar2022 ₹-8.39 -

SUVEN LIFE SCIENCES Return on Capital Employed (ROCE)
[BOM: 530239|NSE : SUVEN]

Y-o-Y

Negative

5 Yr CAGR

Negative

Years ROCE % Change
Mar2026 -78.71%
Negative
Mar2025 -84.51%
Negative
Mar2024 -32.78%
Negative
Mar2023 -49.94%
Negative
Mar2022 -117.81% -

SUVEN LIFE SCIENCES Share Price vs Sensex

Current Share Price : ₹307.1
Current MarketCap: ₹ 8,678.6 Cr
Updated EOD on :Jul 31,2026

Share Price Returns(%) 1 Week 1 Month 1 Year
SUVEN LIFE SCIENCES

-1.5%

2.8%

5.1%

SENSEX

2.7%

1.5%

-5.6%

SUVEN LIFE SCIENCES related INDICES

BSE Indices1W1M1Y
BSE HEALTHCARE 2.8% 3.4% 12.9%
BSE 1000 2.3% 1.5% 0%
No NSE index found

You may also like the below Video Courses


FAQ about SUVEN LIFE SCIENCES Financials


How the annual revenues of SUVEN LIFE SCIENCES have changed ?

The Revenues of SUVEN LIFE SCIENCES have increased by 6.90% YoY .

How the Earnings per Share (EPS) of SUVEN LIFE SCIENCES have changed?

The Earnings Per Share (EPS) of SUVEN LIFE SCIENCES has decreased by Negative YoY .